Moreover, the dominant TCR-Vβ+ expansions in T-LGLL patients were almost exclusively populated with terminally differentiated (CCR7− CD45-RA+) effector CD8+ T-cells, whereas the dominant TCR-Vβ+ expansions in dasatinib-treated CML patients were more broadly constituted across the phenotypic spectrum of CD8+ T-cells (Fig. 2A). This evidence concerns the gene CCR7 and chronic myelogenous leukemia, BCR-ABL1 positive.